Insider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 364 Shares of Stock

Key Points

• CFO James Edgemond sold a total of 100,000 shares of United Therapeutics between March 23 and April 23, raising roughly $56.6 million, including a 364‑share sale on April 22 for $209,609.
• After these transactions he still owns 18,996 shares, valued at about $10.94 million.
• Market context: UTHR traded at $567.16 (down ~1%), has a market cap of $24.86 billion, and carries an average analyst target of $601.50 with a consensus rating of "Moderate Buy."

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 364 shares of United Therapeutics stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $575.85, for a total value of $209,609.40. Following the sale, the chief financial officer owned 18,996 shares in the company, valued at $10,938,846.60. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

James Edgemond also recently made the following trade(s):

• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total value of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total value of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total value of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total value of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $561.50, for a total value of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $593.17, for a total value of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total value of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Stock Down 1.0%

UTHR traded down $5.69 during trading hours on Friday, hitting $567.16. The stock had a trading volume of 264,756 shares, compared to its average volume of 491,071. The company's fifty day simple moving average is $534.64 and its 200 day simple moving average is $493.24. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The stock has a market cap of $24.86 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the firm posted $6.19 EPS. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Corporation will post 27.97 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on UTHR. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, March 12th. Wells Fargo & Company lifted their target price on United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a report on Tuesday, March 31st. UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Finally, HC Wainwright lifted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $601.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Wellington Management Group LLP grew its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. purchased a new position in shares of United Therapeutics during the third quarter worth about $317,617,000. Norges Bank purchased a new position in shares of United Therapeutics during the fourth quarter worth about $293,418,000. Avoro Capital Advisors LLC grew its holdings in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company's stock worth $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.